In the study, which was published in The BMJ, researchers analyzed data from 195 countries and territories using the 2021 ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Neurologists have grappled with a cluster of amyotrophic lateral sclerosis cases in France, where a fondness for a toxic wild ...

REM sleep behavior disorder is characterized by acting out dreams, which may include shouting, kicking and punching during sleep.

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Seventeen patients with Parkinsonism were admitted to this study. All had been referred to us by their physicians, after treatment with several standard medications for relief of this disorder ...